Hikma Pharmaceuticals PLC
LSE:HIK
Hikma Pharmaceuticals PLC
Operating Income
Hikma Pharmaceuticals PLC
Operating Income Peer Comparison
Competitive Operating Income Analysis
Latest Figures & CAGR of Competitors
Company | Operating Income | CAGR 3Y | CAGR 5Y | CAGR 10Y | |
---|---|---|---|---|---|
Hikma Pharmaceuticals PLC
LSE:HIK
|
Operating Income
$622m
|
CAGR 3-Years
6%
|
CAGR 5-Years
7%
|
CAGR 10-Years
6%
|
|
GlaxoSmithKline PLC
LSE:GSK
|
Operating Income
£7.3B
|
CAGR 3-Years
0%
|
CAGR 5-Years
-2%
|
CAGR 10-Years
1%
|
|
AstraZeneca PLC
LSE:AZN
|
Operating Income
$8.6B
|
CAGR 3-Years
27%
|
CAGR 5-Years
14%
|
CAGR 10-Years
11%
|
|
Verona Pharma PLC
NASDAQ:VRNA
|
Operating Income
-$67.6m
|
CAGR 3-Years
3%
|
CAGR 5-Years
-15%
|
CAGR 10-Years
N/A
|
|
Indivior PLC
LSE:INDV
|
Operating Income
$257m
|
CAGR 3-Years
20%
|
CAGR 5-Years
-5%
|
CAGR 10-Years
N/A
|
|
Dechra Pharmaceuticals PLC
LSE:DPH
|
Operating Income
£24.9m
|
CAGR 3-Years
-25%
|
CAGR 5-Years
-11%
|
CAGR 10-Years
3%
|
See Also
What is Hikma Pharmaceuticals PLC's Operating Income?
Operating Income
622m
USD
Based on the financial report for Dec 31, 2023, Hikma Pharmaceuticals PLC's Operating Income amounts to 622m USD.
What is Hikma Pharmaceuticals PLC's Operating Income growth rate?
Operating Income CAGR 10Y
6%
Over the last year, the Operating Income growth was 22%. The average annual Operating Income growth rates for Hikma Pharmaceuticals PLC have been 6% over the past three years , 7% over the past five years , and 6% over the past ten years .